Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9418962 | 0.88 | HTR2A (0.37) | HTR2ATSHR | |
| SCHEMBL597727 | 0.82 | ADRA2A (0.43) | DRD2HTR2CTSHRNPC1RAB9A | |
| SCHEMBL22143740 | 0.78 | TSHR (0.50) | DRD2HTR2CTSHR | |
| SCHEMBL865619 | 0.77 | HTR2A (0.41) | HTR2A | |
| SCHEMBL4644536 | 0.77 | HTR2A (0.37) | HTR2A | |
| SCHEMBL20787299 | 0.77 | HTR2A (0.37) | HTR1ADRD2HTR2CHTR7HRH1 | |
| SCHEMBL18322409 | 0.77 | PNMT (0.43) | HTR2CHTR2BHTR2A | |
| SCHEMBL5353546 | 0.77 | LMNA (0.51) | NPC1RAB9A | |
| SCHEMBL27577152 | 0.76 | TSHR (0.46) | TSHR | |
| SCHEMBL18733583 | 0.75 | MAOA (0.50) | HTR1ADRD2HTR2CHTR7HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113754803-A | Catalyst system and application thereof as catalyst for olefin polymerization | 中国石油化工股份有限公司 | 2021-12-07 | — | — | CN | claimed |
| CN-113754801-A | Solid catalyst for preparing olefin polymer and solid catalyst system | 中国石油化工股份有限公司 | 2021-12-07 | — | — | CN | claimed |
| CN-113754802-A | Catalyst system for olefin polymerization reaction and prepolymerization catalyst composition | 中国石油化工股份有限公司 | 2021-12-07 | — | — | CN | claimed |
| CN-114685703-B | Catalyst compositions comprising fluorided supports and methods of use thereof | 埃克森美孚化学专利公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12344696-B2 | Process to produce low viscosity polyalphaolefins using non-aromatic-hydrocarbon soluble activators | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4010385-B1 | PROCESS TO PRODUCE LOW VISCOSITY POLYALPHAOLEFINS USING NON-AROMATIC-HYDROCARBON SOLUBLE ACTIVATORS | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-20250019593-A1 | RENEWABLE DIESEL PRODUCTION FROM CATALYTIC PYROLYSIS FEEDSTOCK | IFP Energies Nouvelles (FR) | 2025-01-16 | — | — | US | disclosed |
| US-20250011655-A1 | RENEWABLE JET PRODUCTION FROM CATALYTIC PYROLYSIS FEEDSTOCK | IFP Energies Nouvelles (FR) | 2025-01-09 | — | — | US | disclosed |
| US-20240383885-A1 | Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose | MAKSCIENTIFIC, LLC | 2024-11-21 | — | — | US | disclosed |
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-31 | — | — | US | disclosed |
| US-12129429-B1 | Method for paraffin inhibiting | Skaiblue Fund LLC | 2024-10-29 | — | — | US | disclosed |
| CN-101679286-A | Bicyclic substituted pyrazolone azo derivative, preparation method thereof and application thereof in medicine | SHANGHAI HENGRUI PHARM CO LTD | 2010-03-24 | — | — | CN | disclosed |
| CN-101415702-A | Heterocyclic compounds | ASTELLAS PHARMA INC (JP) | 2009-04-22 | — | — | CN | disclosed |
| CN-101171223-A | Catalytic scriabine reaction | FIRMENICH & CIE (CH) | 2008-04-30 | — | — | CN | disclosed |
| EP-0874860-A1 | SUBSTITUTED INDENYL CONTAINING METAL COMPLEXES AND OLEFIN POLYMERIZATION PROCESS | THE DOW CHEMICAL COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
| CN-1156728-A | Olefin polymerization catalyst, process for preparing olefin polymer, and olefin polymer | MITSUI PETROCHEMICAL IND (JP) | 1997-08-13 | — | — | CN | disclosed |
| WO-1997015583-A1 | SUBSTITUTED INDENYL CONTAINING METAL COMPLEXES AND OLEFIN POLYMERIZATION PROCESS | THE DOW CHEMICAL COMPANY (US) | 1997-05-01 | — | — | WO | disclosed |
| EP-0625209-A1 | METHOD FOR ASSAYING THE SOD ACTIVITY BY USING A SELF-OXIDIZABLE COMPOUND NECESSARY FOR ITS IMPLEMENTATION, SELF-OXIDIZABLE COMPOUNDS AND PREPARATION THEREOF. | BIOXYTECH (FR) | 1994-11-23 | — | — | EP | disclosed |
| US-4182896-A | ANTIINFLAMMATORY AGENTS, ANALGESICS | SOCIETE HEXACHIMIE (FR) | 1980-01-08 | — | — | US | disclosed |
| US-4166131-A | ANTIINFLAMMATORY AGENTS, ANTIPYRETICS, ANTIARTHRITIC AGENT | HEXACHIMIE SOCIETE ANONYME (FR) | 1979-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383885-A1 | Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose | CNR1, CNR2, OPRM1 | HTR1A 108/4885DRD2 53/4885HTR2C 38/4885 |
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | HTR1A 4169/4885DRD2 4708/4885HTR2C 3880/4885 |
| US-12344696-B2 | Process to produce low viscosity polyalphaolefins using non-aromatic-hydrocarbon soluble activators | NONO, F2, SCO2 | HTR1A 662/4885DRD2 1050/4885HTR2C 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.